<Important Notes>
The forward-looking statements contained in this presentation are based on the Company’s assumptions and beliefs in the light of information currently available to it and involves known and unknown risks and uncertainties. Accordingly, there is a possibility that actual results and development programs may differ largely from these forecasts, due to a variety of factors. This report contains information on pharmaceutical products (including those under development), and the content of this report is not intended for medical promotion or medical advice. This translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version shall prevail.
- March 7 2022 Notice of Organizational Restructuring and Personnel Appointments at Our Subsidiaries
- December 24 2021 Notification of Partial Changes in Marketing Approval for the Indication of GnRH Antagonist RELUMINA® Tablets (Relgorix) for Endometriosis
- December 16 2021 Notice Regarding the Publication on a Phase 3 Comparative Study for GnRH Antagonist RELUMINA® Tablets (Relugolix) for Endometriosis
- November 1 2021 RaQualia Pharma and ASKA Pharmaceutical Sign Joint Research Agreement
- October 19 2021 Toray and ASKA Conclude Business Collaboration Agreement for Adhesion Barrier
- September 27 2021 Licensing Agreement on Relugolix Combination Tablet in Women's Health Indications
For the previous news releases, please refer to the website of ASKA Pharmaceutical Holdings Co., Ltd.